In the long run, we found that ertugliflozin was not prone to cause symptomatic hypoglycemia, which may be because SGLT2 inhibitors lower blood glycemic levels independent of pancreatic β cell function and insulin resistance [36]. The gene discussed is SLC5A2; the disease is Hypoglycemia.